1 August 2019 - The August 2019 issue of the New Zealand Pharmaceutical Schedule is now available and in effect.

There are two major new listings this month:

• Adalimumab (Humira) for use by patients with Behçet's disease who are refractory to conventional therapy
• Rituximab (Mabthera) for use by patients with neuromyelitis optica spectrum disorder and patients with refractory myasthenia gravis

Humira and Mabthera are not currently registered by MedSafe for use in these patient populations.

Read New Zealand Pharmaceutical Schedule update